Search results for "Piperidine"

showing 10 items of 236 documents

Soothing the seizures of children.

2008

Endocannabinoids are versatile molecules, regulating a variety of functions in the body. Daniele Piomelli explores how recent clinical trials testing rimonabant, an inhibitor of endocannabinoid signaling, for weight loss emerged from studies of individuals with schizophrenia; such trials have spurred basic research into how endocannabinoids affect both energy use and mood. Beat Lutz and Krisztina Monory examine how rimonabant might prove useful for preventing the development of adult epilepsy in response to fever-induced seizures in infants and young children.

AdultModels NeurologicalGeneral Biochemistry Genetics and Molecular BiologySeizures FebrileEpilepsyRimonabantPiperidinesBasic researchWeight lossCannabinoid Receptor ModulatorsmedicineHumansCannabinoid Receptor AntagonistsClinical Trials as TopicEpilepsybusiness.industryGeneral Medicinemedicine.diseaseEndocannabinoid systemClinical trialMoodChild PreschoolCannabinoid receptor antagonistPyrazoleslipids (amino acids peptides and proteins)medicine.symptomRimonabantbusinessNeurosciencemedicine.drugNature medicine
researchProduct

Efficacy and side effects of intravenous remifentanil patient-controlled analgesia used in a stepwise approach for labour: an observational study

2012

Remifentanil has a suitable pharmacological profile for labour analgesia. In this prospective, observational study, intravenous patient-controlled analgesia with remifentanil, using stepwise bolus doses without background infusion, was examined during the first and second stages of labour. Outcomes were pain reduction, maternal satisfaction, maternal and neonatal side effects and remifentanil metabolism in the neonate.Parturients with normal term singleton pregnancies were recruited. The initial remifentanil bolus dose was 0.15 μg/kg, increasing in steps of 0.15 μg/kg, with a 2-min lock-out. Pain scores using a 100 mm visual analogue scale, systolic and diastolic blood pressures, respirator…

AdultRespiratory rateVisual analogue scalemedicine.medical_treatmentSedationRemifentanilBlood PressureRemifentanilYoung AdultBolus (medicine)PiperidinesHeart RatePregnancymedicineHumansPain ManagementProspective StudiesMaternal-Fetal ExchangePain MeasurementLabor PainLabor ObstetricPatient-controlled analgesiabusiness.industryInfant NewbornObstetrics and GynecologyAnalgesia Patient-ControlledAnalgesics OpioidTreatment OutcomeAnesthesiology and Pain MedicinePatient SatisfactionAnesthesiaApgar ScoreAnalgesia ObstetricalFemaleApgar scoremedicine.symptombusinessmedicine.drugIntravenous Patient-Controlled AnalgesiaInternational Journal of Obstetric Anesthesia
researchProduct

Cost analysis of target-controlled infusion-based anesthesia compared with standard anesthesia regimens.

2000

UNLABELLED With the development of new computer-assisted target-controlled infusion (TCI) systems and the availability of short-acting anesthetics, total IV anesthesia (TIVA) has become increasingly popular. The aim of this study was to compare costs of TCI-based anesthesia with two standard anesthesia regimens. Sixty patients undergoing elective laparoscopic cholecystectomy were randomly divided into three groups. Group 1 (TIVA/TCI) received TIVA using a propofol-based TCI system and continuous administration of remifentanil; Group 2 (isoflurane) underwent inhaled anesthesia with isoflurane, fentanyl, and N2O; Group 3 (standard propofol) received fentanyl and N2O and a continuous infusion …

Adultmedicine.medical_specialtyCost-Benefit AnalysisRemifentanilAnesthesia GeneralFentanylPacuRemifentanilDrug Delivery SystemsPiperidinesMedicineHumansInfusions IntravenousPropofolInfusion PumpsAgedbiologyIsofluranebusiness.industryMiddle Agedbiology.organism_classificationSurgeryFentanylRegimenAnesthesiology and Pain MedicineIsofluraneAnesthesiaAnestheticAnesthetics Inhalationmedicine.symptombusinessPropofolPostoperative nausea and vomitingAnesthetics Intravenousmedicine.drugAnesthesia and analgesia
researchProduct

Nociceptin/orphanin FQ opioid receptor (NOP) selective ligand MCOPPB links anxiolytic and senolytic effects

2021

Accumulation of senescent cells may drive age-associated alterations and pathologies. Senolytics are promising therapeutics that can preferentially eliminate senescent cells. Here, we performed a high-throughput automatized screening (HTS) of the commercial LOPAC®Pfizer library on aphidicolin-induced senescent human fibroblasts, to identify novel senolytics. We discovered the nociceptin receptor FQ opioid receptor (NOP) selective ligand 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole (MCOPPB, a compound previously studied as potential anxiolytic) as the best scoring hit. The ability of MCOPPB to eliminate senescent cells in in vitro models was further tested…

Agingmedicine.drug_classNarcotic AntagonistsNOPMCOPPBSenescenceLigandsAnxiolyticMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePiperidinesSenotherapeuticsOpioid receptormedicineAnimalsHumansSenolyticCaenorhabditis elegansReceptorSenolyticCellular Senescence030304 developmental biology0303 health sciencesNOPSenolytic.ChemistryLigand (biochemistry)High-Throughput Screening Assays3. Good healthCell biologyAnalgesics OpioidNociceptin receptorAnti-Anxiety AgentsOpioid PeptidesReceptors OpioidOriginal ArticleGeriatrics and Gerontology030217 neurology & neurosurgeryGeroScience
researchProduct

Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral mod…

2015

A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl) pyrrolo[1,…

AgonistAM251MaleCannabinoid receptorIndazolesmedicine.drug_classmedicine.medical_treatmentMorpholinesHippocampusPharmacologyNaphthalenesNitric OxideHippocampusSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1medicineAnimalshippocampus temporal lobe epilepsy cannabinoids behavior percentage of protection electrophysiology.Rats WistarWIN 55212-2Cannabinoid Receptor AgonistsDose-Response Relationship DrugCannabinoidsGeneral NeurosciencePilocarpinemedicine.diseaseEndocannabinoid systemBenzoxazinesRatsDisease Models AnimalEpilepsy Temporal LobePyrazolesCannabinoidNitric Oxide SynthasePsychologyNeurosciencemedicine.drug
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference.

2009

The present study employs a conditioned place preference procedure (CPP) to examine the effects of exposure to the cannabinoid agonist WIN 55212-2 (WIN) (0.1 and 0.5mg/kg) during adolescence on the reinforcing properties of +/-3,4-methylenedioxymetamphetamine hydrochloride (MDMA) (1.25 and 2.5mg/kg) in mice. On postnatal day (PD) 27, animals received a daily injection of the assigned treatment on 5 consecutive days, and three days later the place conditioning procedure was initiated (PD 35). The results suggest that pre-exposure to cannabinoids strengthens the properties of MDMA and favors reinstatement of the craving for the drug, which endorses the gateway hypothesis.

AgonistMaleReinforcement ScheduleTime Factorsmedicine.drug_classmedicine.medical_treatmentMorpholinesN-Methyl-34-methylenedioxyamphetamineSpatial BehaviorCravingPharmacologyNaphthalenesDevelopmental psychologyExtinction PsychologicalMiceRimonabantPiperidinesmedicineAnimalsDrug InteractionsCannabinoid Receptor AntagonistsBiological PsychiatryPharmacologyAnalysis of VarianceDose-Response Relationship DrugMDMAExtinction (psychology)Calcium Channel BlockersConditioned place preferenceBenzoxazinesAnimals NewbornHallucinogensCannabinoid receptor antagonistConditioning OperantPyrazolesCannabinoidmedicine.symptomRimonabantPsychologypsychological phenomena and processesmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Coupling between agonist and chloride ionophore sites of the GABA(A) receptor: agonist/antagonist efficacy of 4-PIOL.

2000

Eight gamma-aminobutyric acid (GABA) mimetics were tested on their ability to differentiate native GABA(A) receptor subtypes present in various rat brain regions. In rat brain cryostat sections, little regional variations by the agonistic actions of muscimol, thiomuscimol, 4,5,6,7-tetrahydroisoazolo(5,4-c)pyridin-3-ol, piperidine-4-sulphonic acid, taurine and beta-alanine on [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding to GABA(A) receptor channels were found. They were very similar to those found for GABA itself and indicated no direct correlation with single subunit distributions for any of these compounds. Only the low-efficacy GABA mimetic 5-(4-piperidyl)isoxazol-3-ol (4-PIOL…

AgonistMalemedicine.medical_specialtyAgonist-antagonistmedicine.drug_classBiologyLigandsPartial agonistGABAA-rho receptorCell Linechemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsHumansRats WistarReceptorGABA AgonistsPharmacologyIonophoresGABAA receptorBrainIsoxazolesBridged Bicyclo Compounds HeterocyclicReceptors GABA-ARatsEndocrinologyMuscimolchemistryThiomuscimolEuropean journal of pharmacology
researchProduct

Involvement of tachykinin NK2 receptors in the modulation of spontaneous motility in rat proximal colon.

2000

The role of endogenous tachykinins and the mechanisms whereby they act on NK2 receptors, modulating spontaneous motility, were investigated in rat isolated proximal colon. The mechanical activity was detected as changes in intraluminal pressure. The NK2 receptor antagonist, MEN 10627, produced a concentration-dependent reduction of the contraction amplitude. [beta-Ala8]-neurokinin A(4-10), an NK2 receptor agonist, and [Sar9, Met(O2)11]-Substance P ([Sar9, Met(O2)11]-SP), an NK1 receptor agonist, induced a concentration-dependent contractile response, characterized by an increase in basal tone with superimposed phasic contractions. MEN 10627 antagonized the response to [beta-Ala8]-neurokinin…

AgonistMalemedicine.medical_specialtyPhysiologymedicine.drug_classColonNeurokinin AInhibitory postsynaptic potentialNitric OxidePeptides CyclicTonic (physiology)chemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsEnzyme InhibitorsRats WistarReceptorEndocrine and Autonomic SystemsChemistrymusculoskeletal neural and ocular physiologyGastroenterologyAntagonistReceptors Neurokinin-2RatsEndocrinologyNicotinic agonistNG-Nitroarginine Methyl EsterBenzamidesTetrodotoxinHexamethoniumGastrointestinal MotilityNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct